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a  b  s  t  r  a  c  t
Toxic  aldehydes  produced  by  alcohol  dehydrogenases  have  been  implicated  in the  pathogenesis  of Heli-
cobacter  pylori-related  damage  to  the  gastric  mucosa.  Despite  this,  the  enzymes  that  might  be responsible
for producing  such  aldehydes  have  not  been  fully  described.  It  was,  therefore,  of considerable  inter-
est  to  characterize  the  alcohol  oxidizing  enzymes  in this  pathogen.  Previous  work  in  this  laboratory
characterized  two  such  H. pylori  enzymes  that  had broad  specificity  for a range  of aromatic  alcohol  sub-
strates. An  enzyme  with  broad  specificity  for  aliphatic  alcohols  is likely  to  be required  in order  that  H.
pylori  can  metabolize  the  wide  range  of  substrates  encountered  in  the  gastric  mucosa.  In this  study  we
describe  HpSCADH,  an alcohol  dehydrogenase  from  H. pylori  26695  with  broad  specificity  for  aliphatic
alcohols.  HpSCADH  was  classified  in  the  cD1e  subfamily  of classical  short  chain  alcohol  dehydrogenases.
The  enzyme  was  a monomer  of  approximately  29 kDa with  a preference  for  NAD+ as  cofactor.  Pyrazole
was  found  to be  a competitive  inhibitor  of HpSCADH.
The  physiological  role  of  this  enzyme  was  explored  by construction  of  an HpSCADH  isogenic  mutant.
AtpH  7.0  the  mutant  showed  reduced  growth  which  became  more  pronounced  when  the  pH  was  lowered
to 5.0.  When  pyrazole  was  added  to  wild  type  H. pylori  cells  it caused  growth  profiles  to be  reduced  to  those
of the isogenic  mutant  suggesting  that  HpSCADH  inhibition  alone  was  responsible  for  growth  reduction.
Taken  together,  the data  relating  to  the  alcohol  metabolizing  enzymes  of this  pathogen  indicate  that
they  play  an  important  role  in  H. pylori  growth  and  adaptation  to acidic  environments.  The  therapeutic
potential  of targeting  H. pylori  alcohol  dehydrogenases  is discussed.
© 2013 Published by Elsevier Ltd.
1. Introduction22
Helicobacter pylori is implicated in the pathogenesis of gastric23
lymphoid tissue-associated B-cell lymphoma (Von Herbay et al.,24
1995) and gastric adenocarcinoma in humans (Parsonnet et al.,25
1991). Furthermore, 90–95% of duodenal ulcers in Europe originate26
from H. pylori infection (Krah et al., 2004).27
A role for aldehyde toxicity in the pathogenicity of H. pylori-28
mediated gastric disease has been proposed. Specifically, it was29
suggested that alcohol dehydrogenases of H. pylori contribute its30
pathogenicity by oxidizing alcohols to produce toxic aldehydes:31
the aldehydes then react with and modify proteins in the gastric32
mucosa to cause inflammation. This inflammatory process may33
lead to gastric adenocarcinoma in some cases (Salmela et al., 1997;34
Homann et al., 1997; Salaspuro, 2003; Matysiak-Budnik et al., 1995;35
∗ Corresponding author. Tel.: +353 1 402 4408; fax: +353 1 402 4495.
E-mail address: gary.henehan@dit.ie (G.T.M. Henehan).
Figura, 1997). Ethanol-derived acetaldehyde has been the focus of 36
much of the concern for gastric carcinoma (Salaspuro, 2011). 37
This laboratory has undertaken a systematic study of the pyri- 38
dine linked alcohol oxidizing enzymes of H. pylori. The annotated 39
genome of H. pylori 26695 (Tomb et al., 1997) identifies analdo-keto 40
reductase (HpAKR), a cinnamyl alcohol dehydrogenase (HpCAD) 41
and a putative short chain alcohol dehydrogenasegene (HpSCADH). 42
These pyridine linked oxidoreductases might all be expected to 43
play a role in alcohol oxidation. Two of these enzymes (HpCAD and 44
HpAKR) have been extensively studied in this laboratory (Mee  et al., 45
2005; Cornally et al., 2008). Both HpCAD and HpAKR showed broad 46
substrate specificity for aromatic alcohols. Interestingly, HpAKR 47
was shown to play an important role in the growth of H. pylori 48
under acidic conditions and is thought to be involved in the adap- 49
tation of this bacterium to growth in the gastric mucosa (Cornally 50
et al., 2008). An enzyme with specificity for aliphatic alcohols is pre- 51
sumably necessary to allow this bacterium to catalyze the oxidation 52
of a wider range of physiological substrates. 53
This study identifies an enzyme capable of oxidizing aliphatic 54
alcohols which provides the organism with the ability to 55
1357-2725/$ – see front matter ©  2013 Published by Elsevier Ltd.
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metabolize a broad range of aliphatic and aromatic substrates. The56
physiological role of this dehydrogenase was of considerable inter-57
est since it appeared to be the dominant enzyme in the metabolism58
of non-aromatic alcohols in the organism. To explore this issue59
further an isogenic HpSCADH-negative mutant of H. pylori, was60
constructed using insertional mutagenesis. The mutant showed61
reduced growth compared to the wild type at both neutral and62
acidic pH indicating a role for this dehydrogenase in adaptation63
to the gastric mucosa. We  identify pyrazole as an inhibitor of this64
enzyme and show that this compound can reduce the growth of65
H. pylori in culture.66
2. Materials and methods67
2.1. Cloning of the HpSCADH gene68
All DNA manipulations were performed as described pre-69
viously (Sambrook and Maniatis, 1989). Oligonucleotides used70
for PCR amplification of the HpSCADH gene, using H. pylori71
26695 genomic DNA as template, were designed using the puta-72
tive short chain alcohol dehydrogenase gene sequence from73
H. pylori 26695, available at the NCBI database (NP 207155.1).74
The forward (5′-CGCCATATGGCGCACATT-3′) and the reverse (5′-75
CGCGGATCCAGGGTTTTT ATG GGTG-3′) primers were designed to76
introduce Nde I and BamH I restriction enzyme cleavage sites at the77
N-terminus and C-terminus, respectively. Polymerase Chain Reac-78
tions were performed using a Perkin-Elmer 2400 thermal cycler79
with Taq DNA polymerase (Boerhinger Mannheim, Germany).80
Primers were obtained from Sigma-Genosys (UK). For standard81
amplifications approximately 100 ng of template DNA was  mixed82
with 5 pmol of each specific primer in a reaction volume of 25 l.83
Reactions were performed by denaturing DNA at 94 ◦C for 2 min84
15 s, annealing at 45 ◦C for 30 s and extension at 72 ◦C for 45 s. A total85
of 30 cycles were performed. The amplified PCR product was  cloned86
into pET16(b) (Novagen). The resulting construct was named pET-87
HpSCADH. The positive clones were confirmed by DNA sequencing88
(Eurofins MWG,  Ebensburg, Germany).89
2.2. Purification of the HpSCADH gene product90
Escherichia coli BL21 (DE3) plysS transformed with the pET16(b)-91
HpSCADH construct were grown at 37 ◦C in LB medium containing92
50 g/ml ampicillin. At an OD600 of 0.8 the expression of HpSCADH93
was induced by the addition of 1.0 mM IPTG at 25 ◦C and incubated94
for 14 h with constant shaking (280 rpm). Cells were harvested and95
resuspended in lysis buffer (20 mM Tris–HCl, pH 7.9, 5 mM imidaz-96
ole, 200 mM NaCl) and lysed by sonication for 130 s on ice (VC-75097
ultrasound generator, Sonics and Materials Inc.). Cell debris was98
collected by centrifugation and the supernatant was  applied to a99
nickel-charged iminodiacetic acid column (Novagen) equilibrated100
with lysis buffer. The Ni+ column was washed with 2 l of wash101
buffer, which was  the same as the lysis buffer before elution with102
20 mM Tris–HCl (pH 7.9) containing 200 mM NaCl and 300 mM103
imidazole. Fractions containing purified recombinant HpSCADH104
were identified by SDS-polyacrylamide gel electrophoresis. Posi-105
tive fractions were pooled and dialyzed against 2 l of pre-chilled106
0.2 M potassium phosphate, pH 7.4, for 36 h with three changes.107
2.3. Enzyme assay108
Kinetic parameters were determined spectrophotometrically at109
37 ◦C using an Agilent 8453 diode array spectrophotometer (Agi-110
lent Technologies, Palo Alto, CA, USA). The purified HpSCADH was111
assayed for both the oxidation of alcohols (forward reaction) and112
the reduction of aldehydes (reverse reaction). Activities with alco-113
hols were measured in a final volume of 2.0 ml  in 0.2 M potassium114
phosphate buffer (pH 7.5) containing 0.2 mM NAD+ and alcohol 115
substrate, typically 50 mM for ethanol. The formation of NADH at 116
340 nm was followed. The molar extinction coefficient (ε) used (pH 117
7.5) was  ε340 = 6220 M−1 cm−1 for NADH. The oxidation of cinnamyl 118
alcohol or reduction of cinnamaldehyde was monitored at 366 nm 119
(Larroy et al., 2003). Steady-state parameters were determined by 120
fitting initial rates to the Michaelis–Menten equation using ENZ- 121
FITTER (Elsevier Biosoft, Cambridge, UK). 122
Activities towards different aldehydes were assayed in a 2 ml 123
reaction mixture containing 0.2 M potassium phosphate buffer (pH 124
7.5) with 0.2 mM NADH and varying aldehyde concentrations. The 125
decrease in NADH absorbance at 340 nm was  followed to measure 126
enzyme activity. 127
2.4. Effect of pH and temperature on HpSCADH activity 128
The optimum pH for HpSCADH activity was determined in a 2 ml 129
assay mixture containing 0.2 mM NADH/NAD+ and 1 mM propi- 130
onaldehyde/50 mM 1-propanol as substrates for the reduction and 131
oxidation half reactions respectively, in a standard assay mixture 132
at 37 ◦C. Different pH values were generated using the following 133
buffers: pH 4–5: 50 mM sodium citrate, pH 6–8: 50 mM potassium 134
phosphate and pH 9–10: 50 mM glycine. 135
To examine the effect of temperature, HpSCADH was  assayed in 136
the temperature range 20–60 ◦C in a 2 ml  assay mixture contain- 137
ing 0.2 mM NAD+, 50 mM of 1-propanol as substrate and ∼11 g of 138
HpSCADH ml−1 of assay mixture. The activity at various tempera- 139
tures was studied by incubating the enzyme in 0.2 M potassium 140
phosphate buffer (pH 7.5) at different temperatures for 30 min. 141
Each sample was  then assayed for residual activity. 142
2.5. Bacterial strains and plasmids 143
H. pylori strains 26695 and 1061 were originally obtained 144
from A. Van Vliet and J. Kusters (Erasmus MC  University Med- 145
ical Centre, Rotterdam, The Netherlands). The wild type strains 146
were maintained on Columbia Blood Agar plates containing 5% 147
(v/v) defibrinated horse blood while the medium for the HpSCADH 148
mutant was  supplemented with kanamycin (20 g/ml) for selec- 149
tion. Plates were incubated in a microaerophilic-humidified 150
atmosphere generated using a MART Anoxomat system (Lichten- 151
voorde, the Netherlands). For liquid culture, strains were grown 152
in Brucella Broth (Sigma) supplemented with 7% (v/v) foetal calf 153
serum. Cultures were grown in 25 cm2 cell culture flasks with con- 154
stant shaking (120 rpm) at 37 ◦C in an orbital incubator shaker. 155
An acidic environment was created using Brucella broth which 156
was adjusted to the desired pH using 0.1 M HCl (after the addition 157
of foetal calf serum) and subsequently filter sterilized. E. coli was 158
grown in LB broth and on LB agar, as required. The antibiotics used 159
for selection purposes were ampicillin (50 g/ml) and kanamycin 160
(20 g/ml). 161
2.6. DNA manipulations 162
All DNA manipulations were carried out according to standard 163
procedures (Sambrook and Maniatis, 1989). Transformation of 164
E. coli cloning host (DH5; Invitrogen) was performed accord- 165
ing to the manufacturer’s protocol. Natural transformation of H. 166
pylori with plasmid constructs was carried out as described in 167
Smeets et al. (2000).  All oligonucleotide primers were obtained 168
from Eurofins MWG  (Ebensburg, Germany). 169
2.7. Construction of HpSCADH isogenic mutant 170
The HpSCADH gene was  inactivated in H. pylori strain 1061 171
by gene disruption. The purified PCR-amplified Hp0357 (HpSCADH 172
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Fig. 1. Sequence alignment of short chain alcohol dehydrogenases from different strains of H. pylori. Clustal W alignment of HpSCADH from H. pylori 26695 against short
chain  alcohol dehydrogenase/reductases (SDR) from various strains of H. pylori. Sequence similarity is indicated by (dark gray) exact matches, (light gray) strong similarity,
(no  shading) weak similarity. Conserved motifs typical of classical SDRs such as N-terminal cofactor binding site (yellow), active site (blue), a conserved part of the active site
(pink), aspartic acid at position 55 (red) and central -sheet stabilizing motif (green) were present in HpSCADH as well as in the SDRs from various other strains of H. pylori.
Clustal W sequence alignment was imported to Genedoc (http://www.psc.edu) for manipulation of the aligned sequences. (For interpretation of the references to color inQ4
this figure legend, the reader is referred to the web  version of the article.)
gene) was ligated into the  cloning vector pGEM-T Easy (Promega)173
by TA cloning and transformed into E. coli DH5. The primers174
used to amplify Hp0357 were: 5′-ATGGCGCACATTTTAGTTAGCGG-175
3′ as the forward primer and 5′-AGGGTTTTTATGGGTGGGTAG-3′ as176
the reverse primer. A 1.5-kb PCR product from plasmid pJMK30177
containing a gene encoding resistance to kanamycin was ampli-178
fied using 5′-TGATCAGTAAAACGACGGCCAGT-3′ as forward primer179
and 5′-TGATCAAACAGCTATGACCATG-3′ as reverse primer. The PCR180
amplified kanamycin cassette (aphA-3) containing the unique Bcl I181
site at both ends was subcloned into pGEM-T Easy vector (Promega)182
by TA cloning and transformed into E. coli DH5 (Invitrogen). Plas-183
mid  DNA isolated from dam+ E. coli (e.g. DH5) is completely184
resistant to cleavage by Bcl I, which cleaves at GATC sites. These sites185
are blocked by dam methylation (methylation at the N6 position of186
the adenine in the sequence 5′-GATC-3′). This was circumvented by187
transforming the pGEM:HpSCADH and pGEM:aphA-3 constructs188
into a dam−/dcm− strain of E. coli (New England Biolabs, Herts,189
England).190
Both pGEM:Hp0357 and pGEM:aphA-3 (isolated from191
dam−/dcm− E. coli) were digested with Bcl I to generate cohe-192
sive ends. The Bcl I digested kanamycin cassette was  cloned into193
the unique Bcl I site within the coding region of HpSCADH gene194
yielding pGEM:HpSCADH::aphA-3 construct (Fig. 5). Disruption195
of the HpSCADH gene by the kanamycin cassette was confirmed196
by DNA sequencing (Eurofins MWG,  Ebensburg, Germany). The 197
mutant construct was used for natural transformation of H. pylori 198
1061. H. pylori genomic DNA was purified using the Wizard® 199
Genomic DNA Purification Kit (Promega, USA). 200
3. Results 201
3.1. Sequence analysis/classification 202
A protein BLAST analysis of HpSCADH revealed the high- 203
est sequence similarity with a number of putative short chain 204
alcohol dehydrogenases and oxidoreductases from pathogens 205
belonging to various bacterial families such as Actinobacil- 206
lus pleuropneumoniae (ZP 00134882.2, 63% identity), Aggregat- 207
ibacter actinomycetemcomitans (YP 003255986.1, 63% identity), 208
Mannheimia haemolytica (ZP 05988835.1, 61% identity), Aeromonas 209
hydrophila (YP 855033.1, 60% identity), Haemophilus influenzae 210
(ZP 04466822.1, 58% identity) and Streptococcus mutans NN2025 211
(YP 003484911.1, 57% identity). 212
Clustal W sequence alignment of HpSCADHs across various 213
strains of H. pylori shows several conserved motifs (Fig. 1). These 214
motifs include an N-terminal cofactor binding site (GxxxGxG, yel- 215
low), the active site motif (YxxxK, blue) and a mid-region conserved 216
site (NNAG, green) (Jornvall et al., 1999; Van der Oost et al., 2001; 217
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Fig. 2. SDS-PAGE of purified HpSCADH. (Lane1) fromleft: purified HpSCADH protein
with an approximate molecular mass of 29 kDa. (Lane 2) protein standard marker
proteins with molecular weight marked on right.
Kallberg et al., 2002). Based on these observations HpSCADH can218
be classified as a classical short chain alcohol dehydrogenase. An219
additional conserved motif (NhxG, pink, Fig. 1), which is involved220
in positioning the active site lysine residue and forming part of221
a postulated proton relay (Filling et al., 2002), is typical of classi-222
cal SCADHs as is the presence of an aspartic acid at position 55 as223
part of the cofactor binding site (Fig. 1, red). The size of HpSCADH224
(250 amino acid residues) is also characteristic of classical SCADHs225
(Kallberg et al., 2002).226
NADH-preferring classical SDRs have an acidic residue at the C-227
terminal of the 2nd beta-strand (key position 36) (Wierenga et al.,228
1985, 1986) unlike NADPH binding enzymes that have two basic229
residues (Tanaka et al., 1996). The HpSCADH sequence contains a230
glutamic acid at position 36 (Fig. 1) indicating that it is expected231
to show a preference for NADH over NADPH. Hence, HpSCADH232
belongs to the cD1e subfamily of the classical NAD(H)-preferring233
SDRs.234
3.2. Expression and purification of HpSCADH235
The recombinant HpSCADH was expressed with an N-terminal236
His-tag. Following purification and dialysis HpSCADH was stored237
in 0.2 M phosphate buffer (pH 7.5) at −20 ◦C. No loss of enzyme238
activity was observed when stored under these conditions for more239
than 1 month. Typically, 1 l of culture yielded ∼5 mg  of purified240
HpSCADH. The HpSCADH eluted from the Ni-column was  ∼95%241
pure as shown by 12% SDS-polyacrylamide electrophoresis gels242
with a relative molecular mass of ∼29 kDa (Fig. 2). Control activity243
measurements with E. coli BL21 (DE3) plysS cell extracts lacking the244
HpSCADH construct showed no short chain alcohol dehydrogenase245
activity.246
Fig. 3. Characterization of HPSCADH: (A) HpSCADH activity as a function of pH for
the  oxidation (red) and reduction (black) half reactions. The buffers used were as
follows: pH 4–5: 0.2 M sodium citrate, pH 6–8: 0.2 M potassium phosphate and pH
9–10: 0.2 M glycine. Assays were carried out at 37 ◦C as described in Section 2. The
assay mixture for the oxidation reaction contained 50 mM 1-propanol while for
reduction 1 mM propionaldehyde was used as substrate. (B) Temperature depend-
ence of HpSCADH activity. Initial rates of HpSCADH mediated oxidation of ethanol
(50 mM)  over a range of temperatures. Activity was measured using standard con-
ditions, as outlined in Section 2. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of the article.)
3.3. Characterization: optimum pH and temperature 247
The activity of HpSCADH was  dependent on pH for both the 248
reduction and oxidation half reactions (Fig. 3A). In the reduc- 249
tion reaction there was  a narrow peak of maximum activity at 250
approximately pH 7.5. The oxidation reaction showed less marked 251
dependence in the pH range of 7–9 with a broad peak centred 252
around pH 9 (Fig. 3A). 253
The effect of temperature on HpSCADH activity is shown in 254
Fig. 3B. The reaction rate increases up to about 38 ◦C and then 255
decreases rapidly. The optimum range was  35–40 ◦C. All experi- 256
ments were carried out in triplicate. 257
3.4. Substrate specificity 258
HpSCADH showed no activity with NADP(H). Its activity was 259
tested with a range of aliphatic and aromatic alcohol/aldehydes, 260
ketones and dicarbonyls (Tables 1A and 1B). Steady-state parame- 261
ters were determined for the most active substrates (Table 2). All 262
assays were carried out at pH 7.5, and at 37 ◦C. 263
Greatest catalytic efficiency with respect to the alcohol sub- 264
strates tested was  seen with 1-propanol which had a kcat/km 265
value of 118.4 s−1 mM−1. The enzyme showed no activity with 266
aromatic alcohols except for a discrete activity with cinnamyl alco- 267
hol. Of the aldehydes evaluated as substrates, butyraldehyde and 268
cinnamaldehyde yielded kcat/km values of 29,198 s−1 mM−1 and 269
540 s−1 mM−1 respectively. Some activity was seen with pyridine 270
aldehydes. 271
The effect of branched chain alcohol substrates on HpSCADH 272
activity was  explored by comparing primary, secondary and ter- 273
tiary butanol. It was found that HpSCADH catalyzed the oxidation 274
of 1-butanol at a rate that was 1.5-fold greater than 2-butanol 275
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Table 1A
Substrate screening of the H. pylori HpSCADH catalyzed oxidation of alcohols.
Substrate Substrate
concentration (mM)
Enzyme activity
(mol/min/mg)
Aliphatic alcohols
Methanol 50 NDA
Ethanol 50 63.2
1-Propanol 50 625.5
2-Propanol 50 110.4
1,2-Propandiol 50 NDA
1-Butanol 50 79.5
2-Butanol 50 54.1
Tert-butanol 50 NDA
2-Methyl-1-butanol 50 NDA
1-Pentanol 50 270
2-Pentanol 10 NDA
4-Penten-1-ol 10 NDA
Hexanol 50 146.9
Octanol 10 NDA
Aromatic alcohols
Benzyl alcohol 10 NDA
4-Methoxybenzylalcohol 10 NDA
4-Nitrobenzyl alcohol 10 NDA
Cyclohexanol 50 NDA
Cinnamylalcohol 10 865.1
Dicarbonyls
Phenylglyoxal 1 94.2
Methylglyoxal 1 155.4
0.2 mM of NAD+ was  used in all assay mixture. The dicarbonyl substrates were
dissolved in 100% methoxyethanol. All alcohol substrates were dissolved in 0.2 M
phosphate buffer (pH 7.5) except hexanol and octanol which were dissolved in 100%
methoxyethanol. NDA is no detectable activity.
while no detectable activity was observed with tertiary butanol.276
Thus, it was clear that the degree of branching strongly influ-277
enced catalysis with straight chain aliphatic substrates being278
optimal. Other aromatic alcohols, aldehydes and ketones showed279
no detectable activity (Tables 1A and 1B). Among the dicarbonyls280
tested HpSCADH showed higher activity towards methylglyoxal281
than phenylglyoxal.282
Table 1B
Substrate screening of the H. pylori HpSCADH catalyzed reduction of aldehydes.
Substrate Substrate
concentration (mM)
Enzyme activity
(mol/min/mg)
Aliphatic aldehydes
Formaldehyde 1 NDA
Acetaldehyde 1 272.9
Butyraldehyde 0.1 575.6
2-Methylbutyraldehyde 1 NDA
Propionaldehyde 0.1 556.9
Valeraldehyde 1 277.9
Hexanal 1 371.5
Octanal 1 1342.2
Crotanaldehyde 1 834.5
Glyceraldehyde 1 NDA
Aromatic aldehydes
Cinnamaldehyde 0.5 509.8
Pyridine 2 aldehyde 1 688.8
Pyridine 4 aldehyde 1 135.6
Benzaldehyde 1 NDA
Ketones
Acetone 50 NDA
Propanone 50 NDA
Butanone 50 NDA
Pentanone 50 NDA
Acetophenone 1 NDA
2,2,2-Trifluroacetophenone 1 NDA
Cyclohexanone 10 NDA
0.2 mM of NADH was used in all assay mixture. All aldehyde and ketone sub-
strates were dissolved in 100% methoxyethanol. NDA is no detectable activity.
Methoxyethanol was not a substrate under these conditions.
Table 2
HpSCADH substrate specificity. Kinetic parameters of HpSCADH from H. pylori.  All
data are mean of triplicate measurements. Assays were carried out as described in
Section 2.
Substrate km (mM) kcat (s−1) kcat/km (s−1 mM−1)
NADHa 0.026 ± 0.0043 362.2 ± 15.4 13932.6
NADa 0.036 ± 0.007 510.8 ± 26.6 14187.5
Acetaldehyde 1.2 ± 0.61 44.0 ± 11.7 52.8
Butyraldehyde 0.0036 ± 0.0003 105.1 ± 1.5 29198.0
Propionaldehyde 0.18 ± 0.002 86.9 ± 1.9 482.7
Valeraldehyde 1.07 ± 0.39 47.9 ± 9.4 44.8
Hexanal 0.99 ± 0.11 63.8 ± 5.6 64.4
Cinnamaldehyde 0.3 ± .06 162.0 ± 14.9 540.0
Ethanol 7.2 ± 0.67 3.0 ± 0.1 0.4
1-Butanol 3.1 ± 0.30 2.7 ± 0.1 0.9
1-Propanol 1.8 ± 0.25 213.1 ± 5.6 118.4
2-Propanol 280.93 ± 73.85 310.1 ± 43.5 1.1
1-Pentanol 12.9 ± 1.11 104.8 ± 2.4 8.1
a Substrate used for the determination of the kinetic constants of NADH and NAD+
was 1 mM butyraldehyde and 50 mM ethanol respectively.
Table 3
Effectors of HpSCADH activity. Q5
Compound Concentration (mM) Relative activity (%)
Pyrazole 0.1 0
Sodium valproate 1 46
Chloral hydrate 1 100
2-Mercaptoethanol 1 100
EDTA 1 78
ZnSO4 b 1 70
MgCl2 1 100
KCl 1 90
a HpSCADH mediated oxidation of 1 mM 1-butanol in a standard assay mixture was
assumed to be the control at 100%. The activity in the presence of various compound
are expressed as the percentage of 1-butanol oxidase activity.
b Initial stock solutions of these compound were prepared in DMSO. All assays
were carried out as described in Section 2. Data are mean of triplicate measurements.
3.5. Inhibition studies 283
The influence of various effector molecules on HpSCADH activ- 284
ity is summarized in Table 3. The presence of Mg2+ and K+ had 285
no significant effect on HpSCADH activity while ZnSO41 showed 286
mild inhibition. EDTA at 1 mM concentration reduced the enzyme 287
activity by ∼22%. Sodium valproate, a potent inhibitor of manyaldo- 288
keto reductases (Hinshelwood et al., 2002; Kuhn et al., 1995; 289
Todaka et al., 2000), was found to inhibit HpSCADH activity by 290
55% at a concentration of 1 mM with little further inhibition seen 291
at elevated concentrations. Chloral hydrate showed no inhibi- 292
tion. Treatment with 2-mercaptoethanol had no effect on the 293
enzyme. 294
Pyrazole is a known potent inhibitor of many alcohol dehy- 295
drogenases with Ki values typically in the low micromolar region 296
(Goldberg and Rydberg, 1969; Li and Theorell, 1969; Reynier, 1969). 297
HpSCADH activity was  found to be fully inhibited by 100 M 298
pyrazole (Table 3). Inhibition was  of a competitive-type with 299
respect to 1-butanol (Fig. 4) and a Ki of 10.05 ± 0.03 M was 300
estimated. 301
3.6. Disruption of HpSCADH by insertional mutagenesis and 302
characterization of the isogenic mutant 303
HpSCADH was markedly specific for aliphatic alcohols which 304
made it interesting to evaluate its role in alcohol and aldehyde 305
1 Initial stock solutions of these compounds were prepared in DMSO. All assays
were carried out as described in Section 2. Data are mean of triplicate measurements.
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Fig. 4. Kinetics of pyrazole inhibition. Competitive inhibition plot for estimation of
Ki (10.05 ± 0.03 M)  for pyrazole. Plot of reciprocal of rate 1/v  versus 1/1-butanol
concentration at increasing inhibitor concentrations (pyrazole). The concentrations
of pyrazole employed were 0, 10, 20, 30 and 50 M.  Data points for individual lines
were fitted to the Michaelis–Menten equation to estimate km (inset). The plot of the
apparent km values against the pyrazole concentration was  linear.
metabolism in the organism. This was explored by generating an306
isogenic mutant of HpSCADH. The mutant was generated by inser-307
tion of a kanamycin antibiotic resistance cassette within the coding308
region of the HpSCADH gene (Fig. 5).309
H. pylori 1061 (wild type) and HpSCADH mutant strains were310
grown under standard microaerobic conditions in Brucella broth311
medium supplemented with FCS (7%, v/v) at pH 7.0. The optical312
density of the liquid cultures was monitored at 600 nm every 6 h313
over a period of 48 h (Fig. 6A). It is evident from the growth pro-314
files that the HpSCADH mutant was compromised compared to315
the parental strain at pH 7.0 suggesting a role for HpSCADH in the316
metabolism/growth of H. pylori. The growth of the isogenic mutant317
was even further compromised under acidic conditions (Fig. 6B).318
This finding was of particular interest since a previous report from319
this laboratory showed that H. pylori (HpAKR) played a role in acid320
adaptation (Cornally et al., 2008) it seems that the HpSCADH is321
somewhat similar. Growth characteristics at a pH 6.0 for both the322
wild type and HpSCADH mutant strains were similar to those seen323
at pH 7.0 (data not shown). The growth rate of both the wild type324
and the mutant were compromised at pH 5.0 (Fig. 6B). The growth325
rate of the HpSCADH mutant was severely compromised beyond326
8 h of growth, compared to the wild type.327
3.7. Effect of pyrazole on the growth of wild type and HpSCADH328
negative mutant of H. pylori 1061329
In this study we have shown that pyrazole is an inhibitor of330
HpSCADH. It has also been shown that knockout of this enzyme331
causes growth inhibition of H. pylori (Fig. 6A). It was, therefore, of332
interest to assess the growth of this mutant H. pylori compared to333
the wild type, in the presence and absence of pyrazole.334
The wild type H. pylori showed impaired growth in the pres-335
ence of 20 M pyrazole similar to the HpSCADH mutant without336
pyrazole (Fig. 7). The growth of the HpSCADH mutant H. pylori was337
unaffected by the presence of the same concentration of pyrazole338
up to 22 h (Fig. 7). However, the mutant did show reduced growth339
after 22 h.340
4. Discussion341
4.1. Sequence analysis342
HpSCADH showed high sequence identity to other puta-343
tive short chain alcohol dehydrogenases from various bacterial344
pathogens. Its preference for NAD(H) over NADP(H) serves345
to group HpSCADH with other NAD(H) preferring SDRs such346
as 3,20-hydroxysteroid dehydrogenase, 7-hydroxysteroid347
Fig. 5. Integration of the aphA-3 disrupted HpSCADH into the genome of H. pylori
1061. 0.8% agarose gel indicating the presence of the inserted aphA-3 cassette in the
HpSCADH negative mutant of H. pylori 1061. Lanes 2 and 3 show a 1.5 kb increase in
size of the HpSCADH gene (chromosomal) due to the presence of the inserted aphA-
3  cassette amplified from H. pylori 1061. Lane 1 contains the HpSCADH gene, with
an  approximate size of 750 bp, amplified from the parental wild type H. pylori 1061.
Lane M contains the 1 kb DNA ladder (Promega). PCR was carried out as described
in Section 2.
dehydrogenase, 2,3-dihydroxybiphenyl dehydrogenase, 2,3- 348
butanediol dehydrogenase, 3-hydroxyacyl-CoA dehydrogenase 349
type 2 and dihydropteridine reductase that also have an acidic 350
residue at position 36. This acidic residue interacts with the 2′- 351
and 3′-hydroxyl groups of the adenine ribose moiety in enzymes 352
that are NAD(H)-binding (Wierenga et al., 1985). 353
Sequence alignment studies with the sequence of highest iden- 354
tity showed that most of the conserved motifs of SDRs are found in 355
the HpSCADH gene sequence. 356
4.2. Substrate specificity 357
Short-chain alcohol dehydrogenases/reductases (SDR) are a 358
large superfamily of proteins with a large diversity of functions 359
such as lipid, carbohydrate, amino acid or xenobiotic metabolism. 360
HpSCADH has a clear preference for aliphatic alcohols. km val- 361
ues were generally within 0.1–2 mM for aldehyde substrates and 362
1–15 mM for alcohol substrates with the exception of 2-propanol, 363
for which a higher km was  obtained (280 mM). HpSCADH showed 364
no detectable activity towards range of aromatic alcohols alde- 365
hydes, dicarbonyls and ketones tested in this study. A discrete 366
activity with cinnamaldehyde was  observed for HpSCADH. This is 367
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Fig. 6. Growth profiles of the isogenic HpSCADH negative mutants of H. pylori at
neutral and acidic conditions. (A) The growth characteristics of both H. pylori 1061
wild type (red) and HpSCADH knockout mutant (blue) at pH 7.0 in Brucella broth
supplemented with 7% foetal calf serum and kanamycin (20 g/ml). (B) The growth
characteristics of both H. pylori 1061 wild type and HpSCADH mutant in Brucella
broth supplemented with 7% foetal calf serum and kanamycin (20 g/ml) at pH 7.0
(control) and pH 5.0. All results are the mean ± the SEM (n = 4). (For interpretation of
the references to color in this figure legend, the reader is referred to the web  version
of  the article.)
probably due to the fact that the aldehyde group in cinnamalde-368
hyde is more accessible, due to its location relative to the aromatic369
moiety compared to the other aromatic substrates tested in this370
study. Unlike CAD from H. pylori, HpSCADH showed no measur-371
able aldehyde dismutation activity with cinnamaldehyde (data not372
shown).373
These substrate specificity studies point to a separation of374
roles for enzymes involved in alcohol metabolism in H. pylori375
with HpCAD and HpAKR oxidizing mainly aromatic alcohols and376
HpSCADH mainly aliphatic alcohols. Combined they provide the377
organism with the ability to oxidize a wide range of alcohol sub-378
strates.379
Fig. 7. Effect of pyrazole on the growth of H. pylori 1061 wild type and HpSCADH
mutant at pH 7.0. Growth of H. pylori 1061 wild type and HpSCADH negative mutants
in  Brucella broth supplemented with 7% foetal calf serum and kanamycin (20 g/ml)
with and without pyrazole (20 M).  Results are the mean ± the SEM.
The substrate preference for HpSCADH overlaps somewhat with 380
HpCAD which, despite its preference for cinnamaldehyde, will 381
reduce aliphatic aldehydes (acetaldehyde, butyraldehyde and pro- 382
pionaldehyde) albeit poorly. It is worth noting that HpSCADH was 383
capable of reducing pyridine aldehydes which may indicate that 384
while it will oxidize aliphatic aldehydes entering the cell it may  also 385
have a specific role in an as yet unidentified metabolic processes. 386
While this study indicates that the organism is capable of pro- 387
ducing a wide range of aldehydes by oxidation of the corresponding 388
alcohol it is important to note that the reaction catalyzed by these 389
enzymes is freely reversible and that the equilibrium for the reac- 390
tion lies towards alcohol formation. Thus, it seems unlikely that 391
such aldehydes could accumulate in the bacterium. 392
4.3. Inhibition studies 393
HpSCADH was found to be inhibited by various molecules 394
(Table 3). By far the most significant inhibition was  observed 395
with pyrazole. This proved to be a potent competitive inhibitor 396
of HpSCADH. While pyrazole is best known as an inhibitor of the 397
medium-chain Zn containing alcohol dehydrogenases (see Shafqat Q3 398
et al., 1999) it has been shown to inhibit the Drosophila short chain 399
alcohol dehydrogenase in a similar manner to the inhibition seen 400
here for HpSCADH (Winberg et al., 1999). 401
The reduced growth profiles of the wild type H.  pylori,  in the 402
presence of micromolar concentrations of pyrazole, suggest that 403
this growth inhibitory effect is mediated through the inhibition of 404
the HpSCADH enzyme. 405
Interestingly, Copeland et al. (2000) reported the synthesis of 406
a class of pyrazole-based compounds that are amongst the most 407
selective and potent inhibitors of H. pylori growth described to date. 408
These compounds were designed to target dihydroorotate dehy- 409
drogenase (DHODase), an enzyme of the pyrimidine biosynthesis 410
pathway of H. pylori. This raises the possibility that pyrazole and its 411
derivatives might be combined to target both HpSCADH and DHO- 412
Dase. Since they target different pathways their growth inhibition 413
might be expected to be additive. Further experiments are required 414
to investigate this possibility. Nonetheless pyrazole inhibition may 415
be useful as an adjunct to other measures to eradicate H. pylori since 416
pyrazole has a long history of use in humans. 417
4.4. Isogenic mutant 418
Initially, it was  believed that the ability of H. pylori to grow in 419
an acidic environment was solely due to the activity of the urease 420
enzyme. The ammonia generated from urease-mediated hydroly- 421
sis of urea was thought to neutralize stomach acid, at least in the 422
microenvironment immediately surrounding the bacterium. How- 423
ever, a report in 2005 described the isolation of a urease-negative 424
strain able to colonize the gastric mucosa suggesting other mecha- 425
nisms are involved (Mine et al., 2005). Previously, we  reported that 426
HpAKR is required for optimum growth under acidic conditions 427
(Cornally et al., 2008). 428
Here, we  have characterized the HpSCADH negative isogenic 429
mutant of H. pylori in terms of growth at both neutral and acidic 430
pH. The data implies a role for HpSCADH in growth over extended 431
periods under these conditions. Impairment of growth of the 432
HpSCADH isogenic mutant may  arise for a number of reasons. For 433
example, loss of this enzyme may  mean that the cell is unable 434
to utilize specific nutrients or to metabolize toxic aldehydes. The 435
process of acid adaptation is undoubtedly a complex process and 436
must be effected quite quickly in order to colonize the gastric 437
mucosa. It is possible that this process produces a number of alco- 438
hols or aldehydes that need to be metabolized rapidly. However, it 439
is worth noting that growth was  not completely halted indicating 440
that compensatory mechanisms that overcome the loss of this 441
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enzyme are present presumably the other alcohol dehydrogenases442
of the cell.443
When we examined the mutant under acid stress the difference444
in growth became more pronounced. The pH of the gastric mucosa445
is believed to vary between pH 4.0 and 6.5 (Bijlsma et al., 2002).446
Indeed, it has been suggested that H. pylori is exposed to the occa-447
sional acid shock as low as pH 2.0 (see Bijlsma et al., 2002; Schreiber448
et al., 2005). Lower pH studies were not pursued but it may  be that449
this growth is even further compromised at pH values below 5.0.450
For the HpAKR mutant previously studied in this laboratory, no451
difference in growth rate between the mutant and the wild type452
was seen at pH 7.0 (Cornally et al., 2008). At reduced pH (pH 5 and453
5.5), the difference in the growth profiles of the wild type and the454
knockout of HpAKR (Cornally et al., 2008) were more dramatic than455
those observed for the HpSCADH mutant (this study). It is possible456
that both HpAKR and HpSCADH play a significant role in the long-457
term colonization of gastric mucosa. Bijlsma et al. (2000) showed458
that acid resistance in H. pylori is a complex function of a num-459
ber of expressed proteins. The present data indicate that HpSCADH460
contributes to this process.461
5. Conclusion462
In conclusion, this work shows the Hp0357 gene product463
(HpSCADH) to be an active short chain alcohol dehydrogenase that464
differs in specificity from the other two oxidoreductases from H.465
pylori in having single cofactor preference (NADH) and exhibiting a466
preference for aliphatic aldehydes. This work also assigns HpSCADH467
as a classical short chain alcohol dehydrogenase. Characterization468
of HpSCADH provides a more complete picture of all the alde-469
hyde/alcohol metabolizing oxidoreductases present in H. pylori,470
demonstrating that a wide range of toxic aldehydes produced as a471
result of metabolism of dietary alcohols, can be efficiently reduced.472
The isogenic HpSCADH negative mutant showed that under the473
conditions used in this study, HpSCADH is important for the growth474
of H. pylori. However, the knockout did not lead to complete inhibi-475
tion of growth which implies that the function of this enzyme can476
be compensated by other enzymes, albeit less efficiently.477
It would be of interest to determine whether the knockout of478
the HpAKR in conjunction with HpSCADH might be sufficient to479
halt growth of the organism i.e.,  whether the inhibitory effect seen480
with knockout of these enzymes is additive and sufficient to justify481
targeting these enzymes as potential therapeutics.482
In recent studies, targeting the dihydroorotate dehydrogenase483
enzyme of the pyrimidine biosynthesis pathway (Copeland et al.,484
2000) has been pursued extensively as a means to inhibit H. pylori485
growth. Significantly, pyrazole is a known therapeutic with a his-486
tory of use in humans while a number of AKR inhibitors have been487
developed for use in humans. It is possible that a combination of488
such existing alcohol dehydrogenase inhibiting compounds might489
be sufficient to prevent H. pylori colonisation of gastric mucosa. The490
advantage of such an approach is that the therapeutics for alcohol491
dehydrogenase inhibition is known compounds. In vivo tests are492
required to explore this notion further.493
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